

# Tetsuo Shoji

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9073623/publications.pdf>

Version: 2024-02-01

122  
papers

7,206  
citations

47006

47  
h-index

58581

82  
g-index

126  
all docs

126  
docs citations

126  
times ranked

6630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1153-1165.	2.0	2
2	Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 220-228.	0.9	3
3	Associations of cardiovascular disease and blood pressure with cognition in hemodialysis patients: The Osaka Dialysis Complication Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1758-1767.	0.7	4
4	Role of adiponectin in the relationship between visceral adiposity and fibroblast growth factor 23 in non-diabetic men with normal kidney function. <i>Endocrine Journal</i> , 2022, 69, 121-129.	1.6	1
5	Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS). <i>Nutrients</i> , 2022, 14, 343.	4.1	2
6	Nutritional Disorder Evaluated by the Geriatric Nutritional Risk Index Predicts Death After Hospitalization for Infection in Patients Undergoing Maintenance Hemodialysis. , 2022, 32, 751-757.		8
7	Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. <i>BMC Nephrology</i> , 2021, 22, 104.	1.8	15
8	Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 599-612.	4.5	19
9	Difficulty in activities of daily living and falls in patients undergoing hemodialysis: A cross-sectional study with nondialysis controls. <i>Hemodialysis International</i> , 2021, 25, 338-347.	0.9	6
10	Oxidative Stress and Inflammation as Predictors of Mortality and Cardiovascular Events in Hemodialysis Patients: The DREAM Cohort. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 249-260.	2.0	21
11	Association of Zinc Deficiency with Development of CVD Events in Patients with CKD. <i>Nutrients</i> , 2021, 13, 1680.	4.1	33
12	Low Free Triiodothyronine Level as a Predictor of Cardiovascular Events and All-Cause Mortality in Patients Undergoing Hemodialysis: The DREAM Cohort. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 1071-1082.	2.0	11
13	Association of Reduced Free T3 to Free T4 Ratio with Lower Serum Creatinine in Japanese Hemodialysis Patients. <i>Nutrients</i> , 2021, 13, 4537.	4.1	6
14	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 409-417.	2.0	29
15	Inter-Arm Blood Pressure Difference in Diabetes Mellitus and Its Preferential Association with Peripheral Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 780-788.	2.0	11
16	Association between Serum Zinc and Calcification Propensity (T50) in Patients with Type 2 Diabetes Mellitus and In Vitro Effect of Exogenous Zinc on T50. <i>Biomedicines</i> , 2020, 8, 337.	3.2	9
17	Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. <i>BMC Nephrology</i> , 2019, 20, 105.	1.8	85
18	Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2019, 18, 167.	6.8	26

#	ARTICLE	IF	CITATIONS
19	Plasma omentin levels are associated with vascular endothelial function in patients with type 2 diabetes at elevated cardiovascular risk. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 160-168.	2.8	31
20	Steno-Stiffness Approach for Cardiovascular Disease Risk Assessment in Primary Prevention. <i>Hypertension</i> , 2019, 73, 508-513.	2.7	9
21	Simultaneously Measured Interarm Blood Pressure Difference and Stroke. <i>Hypertension</i> , 2018, 71, 1030-1038.	2.7	22
22	Plasma soluble leptin receptor levels are associated with pancreatic $\beta$ -cell dysfunction in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2018, 9, 55-62.	2.4	15
23	Altered Serum n-6 Polyunsaturated Fatty Acid Profile and Risks of Mortality and Cardiovascular Events in a Cohort of Hemodialysis Patients. , 2018, 28, 54-63.		6
24	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2325.	7.4	55
25	Ankle-brachial index measured by oscillometry is predictive for cardiovascular disease and premature death in the Japanese population: An individual participant data meta-analysis. <i>Atherosclerosis</i> , 2018, 275, 141-148.	0.8	34
26	Plasma polyunsaturated fatty acid profile is associated with vascular endothelial function in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 352-355.	2.0	5
27	Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease. <i>Hypertension</i> , 2017, 69, 1045-1052.	2.7	382
28	Lipopolysaccharide-binding protein is associated with arterial stiffness in patients with type 2 diabetes: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2017, 16, 62.	6.8	38
29	Plasma homocysteine and cerebral small vessel disease as possible mediators between kidney and cognitive functions in patients with diabetes mellitus. <i>Scientific Reports</i> , 2017, 7, 4382.	3.3	12
30	Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 685-693.	1.6	29
31	Cardiothoracic Ratio as a Predictor of Cardiovascular Events in a Cohort of Hemodialysis Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 412-421.	2.0	24
32	Plasma C1q/TNF-Related Protein-9 Levels Are Associated with Atherosclerosis in Patients with Type 2 Diabetes without Renal Dysfunction. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	2.3	16
33	Visceral Adiposity is Preferentially Associated with Vascular Stiffness Rather than Thickness in Men with Type 2 Diabetes. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1067-1079.	2.0	13
34	Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000265.	2.8	8
35	The heart and vascular system in dialysis. <i>Lancet, The</i> , 2016, 388, 276-284.	13.7	219
36	Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1557-1565.	4.5	9

#	ARTICLE	IF	CITATIONS
37	Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patientsâ€™ rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial. Renal Replacement Therapy, 2016, 2, .	0.7	6
38	A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. Nephron Extra, 2015, 5, 58-66.	1.1	41
39	Current Focuses in Serum Lipid Abnormalities in Dialysis Patients. Blood Purification, 2015, 40, 326-331.	1.8	3
40	Use of Vitamin <sc>D</sc> Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2015, 19, 235-244.	0.9	16
41	Advantage of Insulin Glulisine Over Regular Insulin in Patients With Type 2 Diabetes and Severe Renal Insufficiency. , 2015, 25, 129-134.		19
42	Endocrine and Metabolic Changes Affecting Cardiovascular Disease in Dialysis Patients. , 2015, 25, 223-225.		6
43	Cerebral Microbleeds Predict Intracerebral Hemorrhage in Hemodialysis Patients. Stroke, 2015, 46, 2107-2112.	2.0	31
44	Response to comment on Imamura et al. Plasma polyunsaturated fatty acid profile and delta-5 desaturase activity are altered in patients with type 2 diabetes. Metabolism 2014;63(11):1432â€™8. Metabolism: Clinical and Experimental, 2015, 64, e3-e4.	3.4	0
45	Effect of Chair Stand Exercise on Activity of Daily Living: A Randomized Controlled Trial in Hemodialysis Patients. , 2015, 25, 17-24.		52
46	Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clinical and Experimental Nephrology, 2015, 19, 379-386.	1.6	49
47	Plasma polyunsaturated fatty acid profile and delta-5 desaturase activity are altered in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2014, 63, 1432-1438.	3.4	25
48	Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. Cardiovascular Diabetology, 2014, 13, 10.	6.8	32
49	Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clinical and Experimental Nephrology, 2014, 18, 257-260.	1.6	9
50	Clinical Practice Guideline for the Management of Chronic Kidney Diseaseâ€™Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 2013, 17, 247-288.	0.9	305
51	Overview of Regular Dialysis Treatment in <sc>J</sc>apan (as of 31 <sc>D</sc>ecember 2011). Therapeutic Apheresis and Dialysis, 2013, 17, 567-611.	0.9	132
52	Serum n-3 and n-6 Polyunsaturated Fatty Acid Profile as an Independent Predictor of Cardiovascular Events in Hemodialysis Patients. American Journal of Kidney Diseases, 2013, 62, 568-576.	1.9	66
53	Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2013, 17, 221-228.	0.9	133
54	Disappearance of Association in Diabetic Patients on Hemodialysis between Anemia and Mortality Risk: The Japan Dialysis Outcomes and Practice Pattern Study. Nephron Clinical Practice, 2012, 120, c91-c100.	2.3	20

#	ARTICLE	IF	CITATIONS
55	Decreased serum adrenal androgen dehydroepiandrosterone sulfate and mortality in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3915-3922.	0.7	26
56	Poor muscle quality as a predictor of high mortality independent of diabetes in hemodialysis patients. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 266-270.	5.6	50
57	Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 387-435.	0.9	109
58	Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 299-315.	2.0	67
59	Association of Endothelial and Vascular Smooth Muscle Dysfunction with Cardiovascular Risk Factors, Vascular Complications, and Subclinical Carotid Atherosclerosis in Type 2 Diabetic Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 276-284.	2.0	50
60	Thrice-weekly insulin injection with nurse's support for diabetic hemodialysis patients having difficulty with self injection. <i>Osaka City Medical Journal</i> , 2012, 58, 35-8.	0.4	2
61	Elevated Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1112-1120.	4.5	105
62	Active Vitamin D and Acute Respiratory Infections in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1361-1367.	4.5	26
63	腎臓病と動脈硬化の関連性に関する研究. <i>Nihon Toseki Igakkai Zasshi</i> 2011, 44, 1136-1144.		
64	Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. <i>BMC Nephrology</i> , 2010, 11, 7.	1.8	22
65	Fatigue Is a Predictor for Cardiovascular Outcomes in Patients Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 659-666.	4.5	96
66	Cerebral microbleeds in predialysis patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1554-1559.	0.7	59
67	Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. <i>Atherosclerosis</i> , 2010, 210, 145-149.	0.8	57
68	Central versus peripheral arterial stiffness in association with coronary, cerebral and peripheral arterial disease. <i>Atherosclerosis</i> , 2010, 211, 480-485.	0.8	78
69	Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. <i>Atherosclerosis</i> , 2009, 202, 582-588.	0.8	58
70	Plasma angiotensin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia. <i>Atherosclerosis</i> , 2009, 207, 579-584.	0.8	18
71	Reverse epidemiology in hemodialysis patients. Lessons from Japanese registries. <i>Nephrologie Et Therapeutique</i> , 2008, 4, 223-227.	0.5	3
72	Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2329-2336.	0.7	14

#	ARTICLE	IF	CITATIONS
73	Association between Plasma Angiopoietin-Like Protein 3 and Arterial Wall Thickness in Healthy Subjects. <i>Journal of Vascular Research</i> , 2007, 44, 61-66.	1.4	54
74	Body fat measurement in chronic kidney disease: implications in research and clinical practice. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 572-576.	2.0	2
75	1. ä;å~æœÿè...Žă,â...”ă«ăăăăă,ăăœè,,^çj~ăCE-ă@ă@šé†è©•ă¾¼j. <i>Nihon Toseki Igakkai Zasshi</i> , 2007, 40, 130-131.	0.1	1
76	Body Composition and Cardiovascular Risk in Hemodialysis Patients. , 2006, 16, 241-244.		13
77	Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 996-1001.	3.4	36
78	Regional Arterial Stiffness Associated with Ischemic Heart Disease in Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 114-121.	2.0	45
79	Plasma Lipoprotein Abnormalities in Hemodialysis Patients”Clinical Implications and Therapeutic Guidelines. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, 305-315.	0.9	30
80	Vitamin D, Cardiovascular System, and Longevity of Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, S27-S33.	0.9	1
81	Does paricalcitol reduce proteinuria in patients with chronic kidney disease?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 352-353.	2.0	3
82	Regional Arterial Stiffness in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2245-2252.	6.1	108
83	Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis. <i>Diabetes Care</i> , 2006, 29, 1496-1500.	8.6	176
84	Chronic Kidney Disease as a Metabolic Syndrome with Malnutrition-Need for Strict Control of Risk Factors. <i>Internal Medicine</i> , 2005, 44, 179-187.	0.7	42
85	Cross-Sectional Association of Serum Phosphate With Carotid Intima-Medial Thickness in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 859-865.	1.9	46
86	Effect of Atorvastatin on Regional Arterial Stiffness in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 205-210.	2.0	76
87	Altered relationship between body fat and plasma adiponectin in end-stage renal disease. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 330-334.	3.4	46
88	Lower risk for cardiovascular mortality in oral 1Î-hydroxy vitamin D3 users in a haemodialysis population. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 179-184.	0.7	346
89	Molecular forms of adiponectin in uraemic plasma. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1937-1938.	0.7	15
90	Arterial stiffness in predialysis patients with uremia. <i>Kidney International</i> , 2004, 65, 936-943.	5.2	119

#	ARTICLE	IF	CITATIONS
91	Roles of metabolic and endocrinological alterations in atherosclerosis and cardiovascular disease in renal failure: Another form of metabolic syndrome. <i>Seminars in Nephrology</i> , 2004, 24, 423-425.	1.6	16
92	Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2003, 41, S76-S79.	1.9	129
93	Body fat mass in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2003, 41, S137-S141.	1.9	18
94	Non-HDL-C as a predictor of cardiovascular mortality in patients with end-stage renal disease. <i>Kidney International</i> , 2003, 63, S117-S120.	5.2	69
95	The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. <i>Kidney International</i> , 2003, 63, S128-S130.	5.2	24
96	Arterial wall stiffness is associated with peripheral circulation in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2003, 170, 87-91.	0.8	48
97	Preferential Stiffening of Central Over Peripheral Arteries in Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 448-452.	0.6	202
98	Pulse Wave Velocity in Lower-Limb Arteries among Diabetic Patients with Peripheral Arterial Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2003, 10, 253-258.	2.0	116
99	Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1894-1900.	6.1	339
100	Advanced atherosclerosis in predialysis patients with chronic renal failure. <i>Kidney International</i> , 2002, 61, 2187-2192.	5.2	146
101	Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. <i>Kidney International</i> , 2002, 62, 2230-2237.	5.2	48
102	Effect of Diabetes on Uremic Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 305-313.	2.0	14
103	Femoral artery wall thickness and stiffness in evaluation of peripheral vascular disease in type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2001, 158, 207-214.	0.8	74
104	Paradox of risk factors for cardiovascular mortality in uremia: Is a higher cholesterol level better for atherosclerosis in uremia?. <i>American Journal of Kidney Diseases</i> , 2001, 38, S4-S7.	1.9	83
105	Atherogenic lipoproteins in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 2001, 38, S30-S33.	1.9	73
106	Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. <i>American Journal of Kidney Diseases</i> , 2001, 38, S186-S190.	1.9	60
107	HOMA Index to Assess Insulin Resistance in Renal Failure Patients. <i>Nephron</i> , 2001, 89, 348-349.	1.8	79
108	Diabetes Mellitus, Aortic Stiffness, and Cardiovascular Mortality in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2117-2124.	6.1	390

#	ARTICLE	IF	CITATIONS
109	Increasing Body Fat Mass in the First Year of Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1921-1926.	6.1	56
110	Antibodies Against Oxidized LDL and Carotid Artery Intima-Media Thickness in a Healthy Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 703-707.	2.4	120
111	Additive impacts of diabetes and renal failure on carotid atherosclerosis. <i>Atherosclerosis</i> , 2000, 153, 257-258.	0.8	59
112	Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. <i>Atherosclerosis</i> , 2000, 148, 171-177.	0.8	161
113	Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. <i>Kidney International</i> , 1999, 56, S134-S136.	5.2	15
114	Secondary Hyperparathyroidism, Decreased Hepatic Triglyceride Lipase, Elevated Intermediate Density Lipoprotein and Atherosclerosis in Hemodialysis Patients. <i>Nephron</i> , 1998, 78, 121-122.	1.8	9
115	Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. <i>Atherosclerosis</i> , 1997, 131, 229-236.	0.8	108
116	Effects of the Nicotinic Acid Analogue Niceritrol on Lipoprotein Lp(a) and Coagulation-Fibrinolysis Status in Patients with Chronic Renal Failure on Hemodialysis. <i>Nephron</i> , 1997, 77, 112-113.	0.6	7
117	Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Carotid Arterial Wall Thickness in Non-Insulin-Dependent Diabetic Patients. <i>Circulation</i> , 1996, 94, 704-707.	1.6	85
118	High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. <i>Kidney International</i> , 1995, 48, 820-826.	5.2	284
119	Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: Effect of a fibric acid, clofibrate. <i>Kidney International</i> , 1993, 44, 1352-1359.	5.2	26
120	Impaired metabolism of high density lipoprotein in uremic patients. <i>Kidney International</i> , 1992, 41, 1653-1661.	5.2	111
121	Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 1002-1008.	3.4	48
122	Decreased Albuminuria by Pravastatin in Hyperlipidemic Diabetics. <i>Nephron</i> , 1991, 59, 664-665.	1.8	26